诊断学在肿瘤学中的作用：Stefano Buono访谈

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2017-06-09 DOI:10.2217/ije-2017-0014

S. Buono

{"title":"诊断学在肿瘤学中的作用：Stefano Buono访谈","authors":"S. Buono","doi":"10.2217/ije-2017-0014","DOIUrl":null,"url":null,"abstract":"Stefano Buono* speaks to Commissioning Editor, Sebastian Dennis-Beron: Stefano Buono is the Chief Executive Officer, a member of the board of directors, and a founder of Advanced Accelerator Applications (AAA). He has been responsible for overseeing AAA operations, including the development and commercialization of the current portfolio of diagnostic and therapeutic molecular nuclear medicine products, and listing AAA on Nasdaq (stock symbol: AAAP). Prior to founding the company in 2002, he worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4, in Italy. During his 6-year tenure with CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. Before working at CRS4, and alongside his appointment at CRS4, he worked with Physics Nobel Laureate Carlo Rubbia at The European Organization for Nuclear Research (CERN), the world’s largest research laboratory for particle physics, i...","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2017-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2017-0014","citationCount":"1","resultStr":"{\"title\":\"The role of theragnostics in oncology: an interview with Stefano Buono\",\"authors\":\"S. Buono\",\"doi\":\"10.2217/ije-2017-0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Stefano Buono* speaks to Commissioning Editor, Sebastian Dennis-Beron: Stefano Buono is the Chief Executive Officer, a member of the board of directors, and a founder of Advanced Accelerator Applications (AAA). He has been responsible for overseeing AAA operations, including the development and commercialization of the current portfolio of diagnostic and therapeutic molecular nuclear medicine products, and listing AAA on Nasdaq (stock symbol: AAAP). Prior to founding the company in 2002, he worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4, in Italy. During his 6-year tenure with CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. Before working at CRS4, and alongside his appointment at CRS4, he worked with Physics Nobel Laureate Carlo Rubbia at The European Organization for Nuclear Research (CERN), the world’s largest research laboratory for particle physics, i...\",\"PeriodicalId\":42691,\"journal\":{\"name\":\"International Journal of Endocrine Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2017-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/ije-2017-0014\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Endocrine Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/ije-2017-0014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrine Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ije-2017-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

Stefano Buono*与调试编辑Sebastian Dennis Beron交谈：Stefano Bouono是首席执行官、董事会成员，也是高级加速器应用程序（AAA）的创始人。他一直负责监督AAA的运营，包括当前诊断和治疗分子核医学产品组合的开发和商业化，并在纳斯达克上市（股票代码：AAAP）。在2002年创立该公司之前，他曾在意大利高级研究、研究与发展中心（CRS4）担任物理学家。在CRS4的6年任期内，他领导了一个工程师团队，从事能源生产和核废料嬗变领域的不同国际研究项目。在CRS4工作之前，以及在CRS4任职期间，他曾与诺贝尔物理学奖获得者Carlo Rubbia在世界上最大的粒子物理研究实验室欧洲核研究组织（CERN）共事。。。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The role of theragnostics in oncology: an interview with Stefano Buono

Stefano Buono* speaks to Commissioning Editor, Sebastian Dennis-Beron: Stefano Buono is the Chief Executive Officer, a member of the board of directors, and a founder of Advanced Accelerator Applications (AAA). He has been responsible for overseeing AAA operations, including the development and commercialization of the current portfolio of diagnostic and therapeutic molecular nuclear medicine products, and listing AAA on Nasdaq (stock symbol: AAAP). Prior to founding the company in 2002, he worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4, in Italy. During his 6-year tenure with CRS4, he headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. Before working at CRS4, and alongside his appointment at CRS4, he worked with Physics Nobel Laureate Carlo Rubbia at The European Organization for Nuclear Research (CERN), the world’s largest research laboratory for particle physics, i...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.